国泰海通证券股份有限公司 关于仁和药业股份有限公司 调整部分募投项目投资规模并结项、终止部分项目并将相 关募集资金永久补充流动资金的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为 仁和药业股份有限公司（以下简称"仁和药业"或"公司"）2020 年向特定对象 发行股票的保荐机构，根据《证券发行上市保荐业务管理办法》《深圳证券交易 所股票上市规则》《上市公司募集资金监管规则》和《深圳证券交易所上市公司 自律监管指引第 1 号——主板上市公司规范运作》等相关规定，对公司调整部分 募投项目投资规模并结项、终止部分项目并将相关募集资金永久补充流动资金事 项进行了核查，具体情况如下： 单位：万元 | 项目名称 | 募集资金拟投资 | 累计已投入募集 | 结余募集资金 | | --- | --- | --- | --- | | | 总额 | 资金总额 | 金额 | | 数字化保健和消毒抑菌产品生 产线技改搬迁及扩产项目 | 7,962.00 | 6,596.59 | 1,365.41 | | 女性生理健康用品生产线数字 智能化技改搬迁及扩产项目 | 7,963.26 | 5,309.95 | ...

相关募集资金永久补充流动资金的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：000650 证券简称：仁和药业 公告编号：2025-045 仁和药业股份有限公司 关于调整部分募投项目投资规模并结项、终止部分项目并将 | 序号 | 项目名称 | 募集资金承诺投资总 额 | 调整后投资总额 | | --- | --- | --- | --- | | 1 | 仁和翔鹤工业大麻综合利用产业项目 | 27,910.65 | 2,496.58 | | 2 | 中药经典名方产业升级技改项目 | 18,855.00 | 12,428.60 | | 3 | 仁和智慧医药物流园项目 | 22,974.00 | 22,974.00 | | 4 | 仁和研发中心建设项目 | 13,645.00 | 4,146.14 | | 5 | 数字化保健和消毒抑菌产品生产线技 改搬迁及扩产项目 | - | 7,962.00 | | 6 | 女性生理健康用品生产线数字智能化 技改搬迁及扩产项目 | - | 7,963.26 | | 7 | 永久补充流动资金 | - | 25,414 ...

证券代码：000650 证券简称：仁和药业 公告编号：2025-046 仁和药业股份有限公司 关于召开 2025 年第二次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或 重大遗漏。 一、召开会议的基本情况 1、股东会届次：2025 年第二次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所股票上市规则》《深圳 证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等法律、行政法规、部门规章、 规范性文件及《公司章程》的有关规定。 6、会议的股权登记日：2025 年 12 月 19 日 7、出席对象： （1）截至 2025 年 12 月 19 日下午 15:00 收市，在中国证券登记结算有限责任公司深圳分公司登记 在册的本公司全体股东；不能出席现场会议的股东，可以书面形式委托代理人出席会议和参加表决，该 代理人不必是本公司股东； （2）公司董事和高级管理人员； （3）公司聘请的律师。 8、会议地点：江西省樟树市仁和路 36 号公司会议室 二、会议审议事项 1、本次股东会提案编码表 4、会 ...

二、董事会会议审议情况 经与会董事认真审议，会议审议通过了如下议案。 证券代码：000650 证券简称：仁和药业 公告编号：2025-044 仁和药业股份有限公司 第十届董事会第五次会议决议公告 本公司及全体董事会成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 仁和药业股份有限公司（以下简称"公司"）第十届董事会第五次会议通知 于 2025 年 12 月 5 日以直接送达、电子邮件等方式发出，会议于 2025 年 12 月 9 日以现场与通讯结合方式在南昌元创国际 18 层公司会议室召开。会议应到董事 9 人，实到董事 9 人。董事长杨潇先生主持本次会议，公司高管列席会议，会议 符合《中华人民共和国公司法》和《公司章程》的有关规定。 1、审议通过了《关于调整部分募投项目投资规模并结项、终止部分项目并 将相关募集资金永久补充流动资金的议案》。 具体内容详见巨潮资讯网（http://www.cninfo.com.cn）刊登的《关于调整 部分募投项目投资规模并结项、终止部分项目并将相关募集资金永久补充流动资 金的公告》。 本议案已经董事会审计委员会审议通过； ...

（文章来源：证券日报） 证券日报网讯 12月3日，仁和药业在互动平台回答投资者提问时表示，公司目前正努力推动ULOOK眼 镜尽快正式上市销售。 ...

格隆汇12月3日丨仁和药业(000650.SZ)在投资者互动平台表示，公司目前正努力推动ULOOK眼镜尽快 正式上市销售。 ...

Group 1 - The company, Renhe Pharmaceutical, has prioritized the supply of key medications such as Oseltamivir Phosphate, Ibuprofen, and Compound Paracetamol and Amantadine Capsules in response to high market demand [1]

Core Viewpoint - The company, Renhe Pharmaceutical, confirmed the availability of several influenza treatment medications and emphasized its commitment to ensuring stable production and supply to meet market demand [2]. Product Information - The company currently sells influenza treatment medications including Oseltamivir Phosphate Capsules, Ibuprofen Sustained-Release Capsules, Amoxicillin Capsules, Compound Aminophenol and Amantadine Capsules, Strong Loquat Capsules, and Pediatric Acetaminophen Granules [2]. - In addition to these, the company offers various medications for symptoms related to influenza-like illnesses, providing consumers with multiple options for symptomatic relief [2]. Supply Assurance - The company has prioritized the supply of these influenza-related medications to ensure they meet market demand effectively [2].

Group 1: China Construction - The total new contracts signed by China Construction from January to October reached 3.61 trillion yuan, representing a year-on-year increase of 1% [1] Group 2: Changyuan Power - Changyuan Power's subsidiary received approval for the 100MW wind power project in Songzi, Hubei [2] Group 3: China Metallurgical Group - China Metallurgical Group reported a total new contract amount of 845.07 billion yuan from January to October, a decrease of 11.8% year-on-year, while overseas contracts increased by 7.3% to 71.16 billion yuan [4] Group 4: Shapuaisi - Shapuaisi received approval for clinical trials of deoxycorticosterone ketone solution, intended for use during cataract surgery [5] Group 5: Jianfeng Group - Jianfeng Group's subsidiary received approval for clinical trials of a new drug for treating advanced non-squamous non-small cell lung cancer [7] Group 6: Chongqing Steel - Chongqing Steel announced the resignation of its president Meng Wenwang due to work adjustments [8] Group 7: Tianma Technology - Tianma Technology reported an output of approximately 1732.99 tons of eel in October, with a total output of about 15218.73 tons from January to October [10] Group 8: Qingyuan Co. - Qingyuan Co.'s controlling shareholder reduced holdings of convertible bonds by 685,400 units, accounting for 13.71% of the total issuance [11] Group 9: Spring Airlines - Spring Airlines reported a passenger turnover of 506,200.49 million kilometers in October, a year-on-year increase of 20.06% [12] Group 10: China Merchants Port - China Merchants Port reported a total container volume of 17.1714 million TEUs from January to October, a year-on-year increase of 5.1% [13] Group 11: Yangdian Technology - Yangdian Technology announced a change in control following a share transfer [15] Group 12: Wanfu Biology - Wanfu Biology decided to postpone the implementation of its Knowledge City production base project [16] Group 13: Iwu Biology - Iwu Biology terminated the research project for a specific drug, which will reduce its 2025 net profit by approximately 333.79 million yuan [17] Group 14: Hainan Rubber - Hainan Rubber received an insurance payout of 22.9241 million yuan due to revenue loss from rubber price fluctuations [19] Group 15: Xinjiang Tianye - Xinjiang Tianye plans to establish a joint venture with Tianchi Energy to develop coal chemical projects [20] Group 16: China Coal Energy - China Coal Energy's executive director and president Zhao Rongzhe resigned due to reaching retirement age [22] Group 17: Huading Co. - Huading Co. received approval for a stock issuance to specific investors from the Shanghai Stock Exchange [24] Group 18: Zhongmu Co. - Zhongmu Co. decided to waive its right of first refusal for a 4.04% stake in a subsidiary [25] Group 19: Tianlong Co. - Tianlong Co. reported that its subsidiary's stock issuance was approved by the Beijing Stock Exchange [26] Group 20: Hualan Co. - Hualan Co.'s subsidiary plans to invest 20 million yuan in a biotechnology company [27] Group 21: Haichen Pharmaceutical - Haichen Pharmaceutical received a drug registration certificate for a new injection [28] Group 22: Aier Eye Hospital - Aier Eye Hospital plans to invest 300 million yuan in wealth management products [29] Group 23: Xiamen Engineering Machinery - Xiamen Engineering Machinery announced a planned share reduction by a major shareholder [30] Group 24: Guotai Group - Guotai Group successfully acquired 100% of a mining technology company for 110.1 million yuan [31] Group 25: Wanfeng Aowei - Wanfeng Aowei reached a settlement regarding an arbitration matter with a subsidiary [32] Group 26: Taihe Technology - Taihe Technology is undergoing technical upgrades for its ethylene carbonate project [33] Group 27: Renhe Pharmaceutical - Renhe Pharmaceutical's controlling shareholder plans to reduce holdings by 0.21% [34] Group 28: Changshu Bank - Changshu Bank's second-largest shareholder increased its stake to 3.98% [35] Group 29: Overseas Chinese Town A - Overseas Chinese Town A reported a 57% decrease in contract sales in October [36] Group 30: Canadian Solar - Canadian Solar's controlling shareholder expects total revenue of 1.3 to 1.5 billion USD in Q4 2025 [38] Group 31: Zhonggong Education - Zhonggong Education's controlling shareholder's shares will be auctioned due to a loan dispute [40] Group 32: Aikexibo - Aikexibo's shareholders plan to reduce their holdings by up to 3% [42] Group 33: Wanhua Chemical - Wanhua Chemical's shareholder plans to reduce holdings by up to 0.5% [44] Group 34: Jujie Microfiber - Jujie Microfiber's controlling shareholder plans to reduce holdings by up to 2% [45] Group 35: Wangsu Technology - Wangsu Technology's shareholder plans to reduce holdings by up to 1% [46] Group 36: Tianli Lithium Energy - Tianli Lithium Energy received a patent for lithium-ion battery materials [47] Group 37: Heshun Electric - Heshun Electric won a 40 million yuan project for energy storage services [49] Group 38: Changchun High-tech - Changchun High-tech's subsidiary received FDA approval for a clinical trial of a new drug [51] Group 39: Dongrui Co. - Dongrui Co. received an additional export quota for live pigs to Hong Kong [52] Group 40: Zhongwei Co. - Zhongwei Co. set the H-share issuance price at 34 HKD per share [53] Group 41: Fospower Technology - Fospower Technology plans to invest in a lithium sulfide project with partners [54]

Core Viewpoint - The controlling shareholder, Renhe (Group) Development Co., Ltd., plans to reduce its stake in Renhe Pharmaceutical Co., Ltd. due to its own development needs, intending to sell up to 3,000,000 shares, which represents 0.2143% of the company's total share capital [2][5]. Shareholder Holding Situation - As of the announcement date, Renhe (Group) Development Co., Ltd. holds 325,299,386 shares of the company, accounting for 23.2367% of the total shares [2]. Reduction Plan Details - The reduction plan will be executed within three months starting from 15 trading days after the announcement date, through centralized bidding or block trading methods [2][3]. - The number of shares to be reduced will be adjusted if there are changes in the company's capital structure, such as stock dividends or capital increases, but the proportion of the total share capital will remain unchanged [2][4]. Compliance and Commitments - Renhe (Group) Development Co., Ltd. has fulfilled its previous commitments regarding share trading restrictions, which were in place for 36 months after the shares became tradable [4][5]. - The current reduction plan does not conflict with any previously disclosed intentions or commitments [5].